Literature DB >> 26137116

Amplification and protein expression of androgen receptor gene in prostate cancer cells: Fluorescence in situ hybridization analysis.

Xian Zhang1, Shi-Zhe Hong1, Er-Jiang Lin1, DA-Ya Wang1, Zhi-Jia Li1, L I Chen1.   

Abstract

Prostate cancer (PCa) is the most frequently diagnosed non-skin cancer and the second highest cause of cancer-related mortality in adult males worldwide. PCa is highly dependent upon androgen receptor (AR) signaling for cell proliferation and survival. The AR therefore plays a vital role in the development and function of normal and malignant prostate cells or PCa recurrence. The present study aimed to examine the ubiquity of AR amplification in PCa recurrence, even in the absence of androgen. For this purpose, specimens were collected from 37 patients. The amplification of AR and the number of X chromosomes were determined by two-colored fluorescence in situ hybridization analysis. The automated image analysis was used to determine the protein expression of AR. Clinical characteristics and survival in patients whose tumors showed or did not show AR amplification and in X-chromosome polysomy with PCa recurrence has also been compared. The results showed that >35% of patients (13 specimens) exhibited AR amplification. It was also observed that AR was immunostained more intensely in the tumors with amplified AR compared with those tumors with non-amplified AR. This study demonstrated an influential role of AR in tumor growth and progression even after the deprivation of androgen, as well as showing the potential contribution of AR amplification to AR activation even in the relative absence of androgen.

Entities:  

Keywords:  amplification; androgens; fluorescence in situ hybridization; immunohistochemistry; survival

Year:  2015        PMID: 26137116      PMCID: PMC4473505          DOI: 10.3892/ol.2015.3114

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  21 in total

1.  Update on castrate-resistant prostate cancer: 2010.

Authors:  Kiran Lassi; Nancy A Dawson
Journal:  Curr Opin Oncol       Date:  2010-05       Impact factor: 3.645

Review 2.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 4.  Androgen receptor--an update of mechanisms of action in prostate cancer.

Authors:  Z Culig; A Hobisch; G Bartsch; H Klocker
Journal:  Urol Res       Date:  2000-08

5.  Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer.

Authors:  R S D Brown; J Edwards; A Dogan; H Payne; S J Harland; J M S Bartlett; J R W Masters
Journal:  J Pathol       Date:  2002-10       Impact factor: 7.996

6.  Expression, regulation and function of the ISGylation system in prostate cancer.

Authors:  A Kiessling; C Hogrefe; S Erb; C Bobach; S Fuessel; L Wessjohann; B Seliger
Journal:  Oncogene       Date:  2009-05-11       Impact factor: 9.867

7.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

Review 8.  Molecular biology of the androgen receptor.

Authors:  Edward P Gelmann
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

9.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer.

Authors:  T Visakorpi; E Hyytinen; P Koivisto; M Tanner; R Keinänen; C Palmberg; A Palotie; T Tammela; J Isola; O P Kallioniemi
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

10.  Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.

Authors:  P Koivisto; E Hyytinen; C Palmberg; T Tammela; T Visakorpi; J Isola; O P Kallioniemi
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

View more
  10 in total

Review 1.  Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.

Authors:  John L Silberstein; Maritza N Taylor; Emmanuel S Antonarakis
Journal:  Curr Urol Rep       Date:  2016-04       Impact factor: 3.092

2.  Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.

Authors:  Maija P Valta; Hongjuan Zhao; Matthias Saar; Johanna Tuomela; Rosalie Nolley; Johannes Linxweiler; Jouko Sandholm; Jaakko Lehtimäki; Pirkko Härkönen; Ilsa Coleman; Peter S Nelson; Eva Corey; Donna M Peehl
Journal:  Clin Exp Metastasis       Date:  2016-02-12       Impact factor: 5.150

3.  Liquid Biopsies in a Veteran Patient Population With Advanced Prostate and Lung Non-Small Cell Carcinomas: A New Paradigm and Unique Challenge in Personalized Medicine.

Authors:  Sharvari Dalal; Jeffrey Petersen; Darshana Jhala
Journal:  Fed Pract       Date:  2021-01

4.  Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.

Authors:  Stephanie B Greene; Angel E Dago; Laura J Leitz; Yipeng Wang; Jerry Lee; Shannon L Werner; Steven Gendreau; Premal Patel; Shidong Jia; Liangxuan Zhang; Eric K Tucker; Michael Malchiodi; Ryon P Graf; Ryan Dittamore; Dena Marrinucci; Mark Landers
Journal:  PLoS One       Date:  2016-11-16       Impact factor: 3.240

Review 5.  ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer.

Authors:  AbdulFattah Salah Fararjeh; Yen-Nien Liu
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

6.  Biomarkers of Castrate Resistance in Prostate Cancer: Androgen Receptor Amplification and T877A Mutation Detection by Multiplex Droplet Digital PCR.

Authors:  Francis P Young; Therese M Becker; Mohammed Nimir; Thomas Opperman; Wei Chua; Bavanthi Balakrishnar; Paul de Souza; Yafeng Ma
Journal:  J Clin Med       Date:  2022-01-04       Impact factor: 4.241

7.  Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.

Authors:  Junjiang Liu; Yunxia Zhang; Shoubin Li; Fuzhen Sun; Gang Wang; Dong Wei; Tao Yang; Shouyi Gu
Journal:  Oncol Rep       Date:  2021-11-05       Impact factor: 3.906

Review 8.  Androgen receptor in breast cancer: The "5W" questions.

Authors:  Sara Ravaioli; Roberta Maltoni; Barbara Pasculli; Paola Parrella; Anna Maria Giudetti; Daniele Vergara; Maria Maddalena Tumedei; Francesca Pirini; Sara Bravaccini
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-30       Impact factor: 6.055

9.  Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines.

Authors:  Stephen Wilson; Jianfei Qi; Fabian V Filipp
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

10.  SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability.

Authors:  Nanyang Yang; Sitong Liu; Tian Qin; Xintong Liu; Nobumoto Watanabe; Kevin H Mayo; Jiang Li; Xiaomeng Li
Journal:  Cell Commun Signal       Date:  2019-11-21       Impact factor: 5.712

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.